Jump To Section:

Record Information

Version

5.0

Status

Expected but not Quantified

Creation Date

2012-09-06 15:16:49 UTC

Update Date

2022-03-07 02:51:39 UTC

HMDB ID

HMDB0014514

Secondary Accession Numbers

HMDB14514

Metabolite Identification

Common Name

Mirtazapine

Description

Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. [Wikipedia ]

Structure

MOL 3D MOL SDF 3D SDF PDB 3D PDB SMILES InChI

HMDB0251951
     RDKit          3D
Esmirtazapine
 39 42  0  0  0  0  0  0  0  0999 V2000
   -4.0610    0.7887    0.3013 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9896    0.4733   -0.5818 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7567   -0.9264   -0.7370 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8377   -1.5060    0.2885 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5890   -0.7317    0.1997 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5152   -1.6010   -0.0275 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1510   -2.7039   -0.7036 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0393   -3.6765   -1.0349 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3430   -3.4693   -0.6374 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7378   -2.3504    0.0541 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8084   -1.3771    0.3769 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3664   -0.2410    1.1162 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8663    1.0296    0.4841 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9440    1.8605    0.2308 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7789    3.0912   -0.3381 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5241    3.5017   -0.6598 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4393    2.6586   -0.4019 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5726    1.4096    0.1714 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7146    0.6921    0.3513 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8254    1.2853   -0.4416 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9961    0.8784   -0.3235 H   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2436   -0.0327    1.0279 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9245    1.7479    0.8454 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7497   -1.4394   -0.6123 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3932   -1.2144   -1.7338 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6524   -2.5718    0.0218 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1891   -1.4007    1.3259 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.7513   -4.5665   -1.5792 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.0483   -4.2641   -0.9126 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.7693   -2.2393    0.3401 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.9360   -0.2344    2.1506 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.4525   -0.2555    1.1434 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.9363    1.5272    0.4891 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.6597    3.7049   -0.5159 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.4057    4.4759   -1.1087 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5097    3.0782   -0.6896 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9813    0.8530    1.4400 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4612    1.5092   -1.4617 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1709    2.2370    0.0111 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 20  2  1  0
 19  5  1  0
 11  6  1  0
 18 13  1  0
  1 21  1  0
  1 22  1  0
  1 23  1  0
  3 24  1  0
  3 25  1  0
  4 26  1  0
  4 27  1  0
  8 28  1  0
  9 29  1  0
 10 30  1  0
 12 31  1  0
 12 32  1  0
 14 33  1  0
 15 34  1  0
 16 35  1  0
 17 36  1  0
 19 37  1  0
 20 38  1  0
 20 39  1  0
M  END

370
  Mrv0541 02231214382D          

 20 23  0  0  1  0            999 V2000
    3.5989   -0.6297    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2518   -1.5635    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9085   -0.8565    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8852   -0.2861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1965   -0.7403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6732   -1.4514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9951   -1.9214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7090    0.4861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3124   -0.2861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2028    1.1053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9949    1.1053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4887    0.4861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5957   -2.0071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8914    0.5964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9133    1.8778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2732    0.7413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5841    1.3621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0984    2.0071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8823    0.1849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6987   -0.6195    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  4  1  0  0  0  0
  1  6  1  0  0  0  0
  1  9  1  0  0  0  0
  2  5  1  0  0  0  0
  2  7  1  0  0  0  0
  2 13  1  0  0  0  0
  3  9  1  0  0  0  0
  3 20  2  0  0  0  0
  4  5  1  0  0  0  0
  4  8  1  0  0  0  0
  6  7  1  0  0  0  0
  8 10  1  0  0  0  0
  8 14  2  0  0  0  0
  9 12  2  0  0  0  0
 10 11  1  0  0  0  0
 10 15  2  0  0  0  0
 11 12  1  0  0  0  0
 12 16  1  0  0  0  0
 14 17  1  0  0  0  0
 15 18  1  0  0  0  0
 16 19  2  0  0  0  0
 17 18  2  0  0  0  0
 19 20  1  0  0  0  0
M  END
> <DATABASE_ID>
HMDB0014514

> <DATABASE_NAME>
hmdb

> <SMILES>
CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1

> <INCHI_IDENTIFIER>
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

> <INCHI_KEY>
RONZAEMNMFQXRA-UHFFFAOYSA-N

> <FORMULA>
C17H19N3

> <MOLECULAR_WEIGHT>
265.3529

> <EXACT_MASS>
265.157897623

> <JCHEM_ACCEPTOR_COUNT>
3

> <JCHEM_AVERAGE_POLARIZABILITY>
30.350449061099543

> <JCHEM_BIOAVAILABILITY>
1

> <JCHEM_DONOR_COUNT>
0

> <JCHEM_FORMAL_CHARGE>
0

> <JCHEM_GHOSE_FILTER>
1

> <JCHEM_IUPAC>
5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene

> <ALOGPS_LOGP>
2.90

> <JCHEM_LOGP>
3.2079827549999997

> <ALOGPS_LOGS>
-2.38

> <JCHEM_MDDR_LIKE_RULE>
0

> <JCHEM_NUMBER_OF_RINGS>
4

> <JCHEM_PHYSIOLOGICAL_CHARGE>
0

> <JCHEM_PKA_STRONGEST_BASIC>
6.668255157410684

> <JCHEM_POLAR_SURFACE_AREA>
19.37

> <JCHEM_REFRACTIVITY>
82.65530000000001

> <JCHEM_ROTATABLE_BOND_COUNT>
0

> <JCHEM_RULE_OF_FIVE>
1

> <ALOGPS_SOLUBILITY>
1.10e+00 g/l

> <JCHEM_TRADITIONAL_IUPAC>
mirtazapine

> <JCHEM_VEBER_RULE>
1

$$$$

HMDB0251951
     RDKit          3D
Esmirtazapine
 39 42  0  0  0  0  0  0  0  0999 V2000
   -4.0610    0.7887    0.3013 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9896    0.4733   -0.5818 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7567   -0.9264   -0.7370 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8377   -1.5060    0.2885 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5890   -0.7317    0.1997 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5152   -1.6010   -0.0275 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1510   -2.7039   -0.7036 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0393   -3.6765   -1.0349 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3430   -3.4693   -0.6374 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7378   -2.3504    0.0541 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8084   -1.3771    0.3769 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3664   -0.2410    1.1162 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8663    1.0296    0.4841 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9440    1.8605    0.2308 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7789    3.0912   -0.3381 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5241    3.5017   -0.6598 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4393    2.6586   -0.4019 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5726    1.4096    0.1714 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7146    0.6921    0.3513 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8254    1.2853   -0.4416 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9961    0.8784   -0.3235 H   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2436   -0.0327    1.0279 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9245    1.7479    0.8454 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7497   -1.4394   -0.6123 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3932   -1.2144   -1.7338 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6524   -2.5718    0.0218 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1891   -1.4007    1.3259 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.7513   -4.5665   -1.5792 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.0483   -4.2641   -0.9126 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.7693   -2.2393    0.3401 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.9360   -0.2344    2.1506 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.4525   -0.2555    1.1434 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.9363    1.5272    0.4891 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.6597    3.7049   -0.5159 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.4057    4.4759   -1.1087 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5097    3.0782   -0.6896 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9813    0.8530    1.4400 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4612    1.5092   -1.4617 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1709    2.2370    0.0111 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 20  2  1  0
 19  5  1  0
 11  6  1  0
 18 13  1  0
  1 21  1  0
  1 22  1  0
  1 23  1  0
  3 24  1  0
  3 25  1  0
  4 26  1  0
  4 27  1  0
  8 28  1  0
  9 29  1  0
 10 30  1  0
 12 31  1  0
 12 32  1  0
 14 33  1  0
 15 34  1  0
 16 35  1  0
 17 36  1  0
 19 37  1  0
 20 38  1  0
 20 39  1  0
M  END

HEADER    PROTEIN                                 23-FEB-12   NONE
TITLE     NULL                                                        
COMPND    MOLECULE: 370                                               
SOURCE    NULL                                                        
KEYWDS    NULL                                                        
EXPDTA    NULL                                                        
AUTHOR    Marvin                                                      
REVDAT   1   23-FEB-12         0                                  
HETATM    1  N   UNK     0       6.718  -1.175   0.000  0.00  0.00           N+0
HETATM    2  N   UNK     0       4.203  -2.919   0.000  0.00  0.00           N+0
HETATM    3  N   UNK     0       9.163  -1.599   0.000  0.00  0.00           N+0
HETATM    4  C   UNK     0       5.386  -0.534   0.000  0.00  0.00           C+0
HETATM    5  C   UNK     0       4.100  -1.382   0.000  0.00  0.00           C+0
HETATM    6  C   UNK     0       6.857  -2.709   0.000  0.00  0.00           C+0
HETATM    7  C   UNK     0       5.591  -3.587   0.000  0.00  0.00           C+0
HETATM    8  C   UNK     0       5.057   0.907   0.000  0.00  0.00           C+0
HETATM    9  C   UNK     0       8.050  -0.534   0.000  0.00  0.00           C+0
HETATM   10  C   UNK     0       5.979   2.063   0.000  0.00  0.00           C+0
HETATM   11  C   UNK     0       7.457   2.063   0.000  0.00  0.00           C+0
HETATM   12  C   UNK     0       8.379   0.907   0.000  0.00  0.00           C+0
HETATM   13  C   UNK     0       2.979  -3.747   0.000  0.00  0.00           C+0
HETATM   14  C   UNK     0       3.531   1.113   0.000  0.00  0.00           C+0
HETATM   15  C   UNK     0       5.438   3.505   0.000  0.00  0.00           C+0
HETATM   16  C   UNK     0       9.843   1.384   0.000  0.00  0.00           C+0
HETATM   17  C   UNK     0       2.957   2.543   0.000  0.00  0.00           C+0
HETATM   18  C   UNK     0       3.917   3.747   0.000  0.00  0.00           C+0
HETATM   19  C   UNK     0      10.980   0.345   0.000  0.00  0.00           C+0
HETATM   20  C   UNK     0      10.638  -1.156   0.000  0.00  0.00           C+0
CONECT    1    4    6    9                                                  
CONECT    2    5    7   13                                                  
CONECT    3    9   20                                                       
CONECT    4    1    5    8                                                  
CONECT    5    2    4                                                       
CONECT    6    1    7                                                       
CONECT    7    2    6                                                       
CONECT    8    4   10   14                                                  
CONECT    9    1    3   12                                                  
CONECT   10    8   11   15                                                  
CONECT   11   10   12                                                       
CONECT   12    9   11   16                                                  
CONECT   13    2                                                            
CONECT   14    8   17                                                       
CONECT   15   10   18                                                       
CONECT   16   12   19                                                       
CONECT   17   14   18                                                       
CONECT   18   15   17                                                       
CONECT   19   16   20                                                       
CONECT   20    3   19                                                       
MASTER        0    0    0    0    0    0    0    0   20    0   46    0
END

COMPND    HMDB0014514
HETATM    1  C1  UNL     1      -4.129  -0.525   1.123  1.00  0.00           C  
HETATM    2  N1  UNL     1      -2.847  -0.051   0.775  1.00  0.00           N  
HETATM    3  C2  UNL     1      -2.829   1.272   0.201  1.00  0.00           C  
HETATM    4  C3  UNL     1      -1.446   1.674  -0.207  1.00  0.00           C  
HETATM    5  N2  UNL     1      -0.418   0.763   0.163  1.00  0.00           N  
HETATM    6  C4  UNL     1       0.818   1.451   0.307  1.00  0.00           C  
HETATM    7  N3  UNL     1       0.652   2.807   0.240  1.00  0.00           N  
HETATM    8  C5  UNL     1       1.677   3.663   0.350  1.00  0.00           C  
HETATM    9  C6  UNL     1       2.948   3.205   0.537  1.00  0.00           C  
HETATM   10  C7  UNL     1       3.173   1.852   0.612  1.00  0.00           C  
HETATM   11  C8  UNL     1       2.108   0.989   0.497  1.00  0.00           C  
HETATM   12  C9  UNL     1       2.546  -0.415   0.603  1.00  0.00           C  
HETATM   13  C10 UNL     1       1.757  -1.349  -0.204  1.00  0.00           C  
HETATM   14  C11 UNL     1       2.592  -2.187  -0.916  1.00  0.00           C  
HETATM   15  C12 UNL     1       2.091  -3.162  -1.754  1.00  0.00           C  
HETATM   16  C13 UNL     1       0.717  -3.276  -1.862  1.00  0.00           C  
HETATM   17  C14 UNL     1      -0.125  -2.428  -1.142  1.00  0.00           C  
HETATM   18  C15 UNL     1       0.390  -1.471  -0.319  1.00  0.00           C  
HETATM   19  C16 UNL     1      -0.616  -0.667   0.363  1.00  0.00           C  
HETATM   20  C17 UNL     1      -2.049  -0.989   0.001  1.00  0.00           C  
HETATM   21  H1  UNL     1      -4.617  -1.197   0.406  1.00  0.00           H  
HETATM   22  H2  UNL     1      -4.804   0.368   1.277  1.00  0.00           H  
HETATM   23  H3  UNL     1      -4.062  -0.982   2.154  1.00  0.00           H  
HETATM   24  H4  UNL     1      -3.256   1.964   0.956  1.00  0.00           H  
HETATM   25  H5  UNL     1      -3.514   1.336  -0.686  1.00  0.00           H  
HETATM   26  H6  UNL     1      -1.220   2.665   0.248  1.00  0.00           H  
HETATM   27  H7  UNL     1      -1.401   1.857  -1.320  1.00  0.00           H  
HETATM   28  H8  UNL     1       1.438   4.733   0.282  1.00  0.00           H  
HETATM   29  H9  UNL     1       3.787   3.924   0.627  1.00  0.00           H  
HETATM   30  H10 UNL     1       4.160   1.466   0.759  1.00  0.00           H  
HETATM   31  H11 UNL     1       3.621  -0.494   0.363  1.00  0.00           H  
HETATM   32  H12 UNL     1       2.460  -0.760   1.673  1.00  0.00           H  
HETATM   33  H13 UNL     1       3.666  -2.097  -0.831  1.00  0.00           H  
HETATM   34  H14 UNL     1       2.784  -3.788  -2.286  1.00  0.00           H  
HETATM   35  H15 UNL     1       0.331  -4.042  -2.521  1.00  0.00           H  
HETATM   36  H16 UNL     1      -1.194  -2.520  -1.227  1.00  0.00           H  
HETATM   37  H17 UNL     1      -0.576  -0.788   1.489  1.00  0.00           H  
HETATM   38  H18 UNL     1      -2.258  -0.808  -1.076  1.00  0.00           H  
HETATM   39  H19 UNL     1      -2.355  -1.991   0.347  1.00  0.00           H  
CONECT    1    2   21   22   23
CONECT    2    3   20
CONECT    3    4   24   25
CONECT    4    5   26   27
CONECT    5    6   19
CONECT    6    7    7   11
CONECT    7    8
CONECT    8    9    9   28
CONECT    9   10   29
CONECT   10   11   11   30
CONECT   11   12
CONECT   12   13   31   32
CONECT   13   14   14   18
CONECT   14   15   33
CONECT   15   16   16   34
CONECT   16   17   35
CONECT   17   18   18   36
CONECT   18   19
CONECT   19   20   37
CONECT   20   38   39
END

HMDB0251951
     RDKit          3D
Esmirtazapine
 39 42  0  0  0  0  0  0  0  0999 V2000
   -4.0610    0.7887    0.3013 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9896    0.4733   -0.5818 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7567   -0.9264   -0.7370 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8377   -1.5060    0.2885 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5890   -0.7317    0.1997 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5152   -1.6010   -0.0275 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1510   -2.7039   -0.7036 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0393   -3.6765   -1.0349 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3430   -3.4693   -0.6374 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7378   -2.3504    0.0541 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8084   -1.3771    0.3769 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3664   -0.2410    1.1162 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8663    1.0296    0.4841 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9440    1.8605    0.2308 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7789    3.0912   -0.3381 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5241    3.5017   -0.6598 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4393    2.6586   -0.4019 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5726    1.4096    0.1714 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7146    0.6921    0.3513 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8254    1.2853   -0.4416 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9961    0.8784   -0.3235 H   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2436   -0.0327    1.0279 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9245    1.7479    0.8454 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7497   -1.4394   -0.6123 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3932   -1.2144   -1.7338 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6524   -2.5718    0.0218 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1891   -1.4007    1.3259 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.7513   -4.5665   -1.5792 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.0483   -4.2641   -0.9126 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.7693   -2.2393    0.3401 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.9360   -0.2344    2.1506 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.4525   -0.2555    1.1434 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.9363    1.5272    0.4891 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.6597    3.7049   -0.5159 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.4057    4.4759   -1.1087 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5097    3.0782   -0.6896 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9813    0.8530    1.4400 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4612    1.5092   -1.4617 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1709    2.2370    0.0111 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 20  2  1  0
 19  5  1  0
 11  6  1  0
 18 13  1  0
  1 21  1  0
  1 22  1  0
  1 23  1  0
  3 24  1  0
  3 25  1  0
  4 26  1  0
  4 27  1  0
  8 28  1  0
  9 29  1  0
 10 30  1  0
 12 31  1  0
 12 32  1  0
 14 33  1  0
 15 34  1  0
 16 35  1  0
 17 36  1  0
 19 37  1  0
 20 38  1  0
 20 39  1  0
M  END

View in JSmol View Stereo Labels

Synonyms

Value	Source
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine	ChEBI
Mirtazapina	ChEBI
Mirtazapinum	ChEBI
Remeron	Kegg
Reflex	Kegg
Mepirzepine	HMDB
Mirtazepine	HMDB
Celltech brand OF mirtazapine	MeSH, HMDB
Norset	MeSH, HMDB
Organon brand OF mirtazapine	MeSH, HMDB
Rexer	MeSH, HMDB
(N-Methyl-11C)mirtazapine	MeSH, HMDB
Remergil	MeSH, HMDB
6-Azamianserin	MeSH, HMDB
Mundogen brand OF mirtazapine	MeSH, HMDB
Zispin	MeSH, HMDB
Esmirtazapine	MeSH, HMDB
(S)-Mirtazapine	MeSH, HMDB
6 Azamianserin	MeSH, HMDB

Chemical Formula

C₁₇H₁₉N₃

Average Molecular Weight

265.3529

Monoisotopic Molecular Weight

265.157897623

IUPAC Name

5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene

Traditional Name

mirtazapine

CAS Registry Number

61337-67-5

SMILES

CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1

InChI Identifier

InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

InChI Key

RONZAEMNMFQXRA-UHFFFAOYSA-N

Chemical Taxonomy

Description

Belongs to the class of organic compounds known as piperazinoazepines. Piperazinoazepines are compounds containing a piperazinoazepine skeleton, which consists of an azepine ring fused to a piperazine.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Piperazinoazepines

Sub Class

Not Available

Direct Parent

Piperazinoazepines

Alternative Parents

Substituents

Benzazepine
Piperazino-azepine
Dialkylarylamine
Azepine
N-methylpiperazine
N-alkylpiperazine
Aralkylamine
Imidolactam
Benzenoid
Pyridine
Piperazine
1,4-diazinane
Heteroaromatic compound
Tertiary aliphatic amine
Tertiary amine
Azacycle
Amine
Organopnictogen compound
Organonitrogen compound
Organic nitrogen compound
Hydrocarbon derivative
Aromatic heteropolycyclic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

benzazepine (CHEBI:6950 )
tetracyclic antidepressant (CHEBI:6950 )

Ontology

Physiological effect

Not Available

Disposition

Biological location

Non-excretory biofluid

Biofluid or Excreta

Blood (PMID: 21059682)

Excreta

Biofluid or Excreta

Urine (PMID: 21059682)

Cellular substructure

Membrane (HMDB: HMDB0014514)

Source

Exogenous

Exogenous (HMDB: HMDB0014514)

Process

Naturally occurring process

Biological process

Biochemical pathway

Drug action pathway

Mirtazapine H1-Antihistamine Action (PathBank: SMP0062885)

Role

Industrial application

Histamine antagonist (HMDB: HMDB0014514)
H1-receptor antagonist (HMDB: HMDB0014514)
Serotonergic antagonist (HMDB: HMDB0014514)
Alpha-adrenergic antagonist (HMDB: HMDB0014514)

Pharmaceutical industry

Anxiolytic drug (HMDB: HMDB0014514)

Physical Properties

State

Solid

Experimental Molecular Properties

Property	Value	Reference
Melting Point	114 - 116 °C	Not Available
Boiling Point	Not Available	Not Available
Water Solubility	1.1 g/L	Not Available
LogP	2.9	Not Available

Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct Type	Data Source	CCS Value (Å²)	Reference
[M+H]+	CBM	161.0	30932474

Predicted Molecular Properties

Property	Value	Source
Water Solubility	1.1 g/L	ALOGPS
logP	2.9	ALOGPS
logP	3.21	ChemAxon
logS	-2.4	ALOGPS
pKa (Strongest Basic)	6.67	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	19.37 Å²	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	82.66 m³·mol⁻¹	ChemAxon
Polarizability	30.35 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	Yes	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted Chromatographic Properties

Predicted Collision Cross Sections

Predictor	Adduct Type	CCS Value (Å²)	Reference
DarkChem	[M+H]+	161.311	31661259
DarkChem	[M-H]-	159.785	31661259
DeepCCS	[M+H]+	160.507	30932474
DeepCCS	[M-H]-	158.149	30932474
DeepCCS	[M-2H]-	191.035	30932474
DeepCCS	[M+Na]+	166.6	30932474
AllCCS	[M+H]+	162.7	32859911
AllCCS	[M+H-H2O]+	158.9	32859911
AllCCS	[M+NH4]+	166.2	32859911
AllCCS	[M+Na]+	167.3	32859911
AllCCS	[M-H]-	171.6	32859911
AllCCS	[M+Na-2H]-	171.0	32859911
AllCCS	[M+HCOO]-	170.4	32859911

Predicted Kovats Retention Indices

Underivatized

Metabolite	SMILES	Kovats RI Value	Column Type	Reference
Mirtazapine	CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1	3385.6	Standard polar	33892256
Mirtazapine	CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1	2269.6	Standard non polar	33892256
Mirtazapine	CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1	2329.6	Semi standard non polar	33892256

Spectra

GC-MS Spectra

Spectrum Type	Description	Splash Key	Deposition Date	Source	View
Predicted GC-MS	Predicted GC-MS Spectrum - Mirtazapine GC-MS (Non-derivatized) - 70eV, Positive	splash10-0kmr-0190000000-a83848620967f6019b9d	2017-09-01	Wishart Lab	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum - Mirtazapine GC-MS (Non-derivatized) - 70eV, Positive	Not Available	2021-10-12	Wishart Lab	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum - Mirtazapine GC-MS (Non-derivatized) - 70eV, Positive	Not Available	2021-10-12	Wishart Lab	View Spectrum

MS/MS Spectra

Spectrum Type	Description	Splash Key	Deposition Date	Source	View
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-qTof , Positive-QTOF	splash10-001i-0920000000-0a76314cf99840d246ad	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-qTof , Positive-QTOF	splash10-001i-1920000000-27fff664f04384263f02	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-qTof , Positive-QTOF	splash10-014j-0790000000-5653705decf2e797e122	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QTOF , positive-QTOF	splash10-014i-0090000000-57eb768d0827fa54b248	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QTOF , positive-QTOF	splash10-014j-0490000000-4baae8cca5ab43f65dd9	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QTOF , positive-QTOF	splash10-0002-0910000000-c22ff3266fd0a936312d	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QTOF , positive-QTOF	splash10-0002-0900000000-ba0af76733c8ba5925ce	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QTOF , positive-QTOF	splash10-0002-0900000000-1b44d823d26f0e0bcd4d	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-014i-0090000000-3582965e74f282e6bdea	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-014i-3290000000-d8839a66bb5976dbb5fd	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-006t-5930000000-9d1fc48d559a70f6a0e1	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-0002-2910000000-7c8bdce5145b9fd2fda0	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-0002-1900000000-05e225af5ed24498466e	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-0005-1900000000-f4e13abbfa0358ad282c	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-00kf-2900000000-0a101b135d8e91d9b9a2	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-014l-2900000000-6c01bee517524e647dc2	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine LC-ESI-QFT , positive-QTOF	splash10-014u-3900000000-7b5b5e6493206d8c9a67	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine , positive-QTOF	splash10-014j-0890000000-37665999329d651a1038	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine , positive-QTOF	splash10-001i-0920000000-0a76314cf99840d246ad	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine , positive-QTOF	splash10-001i-1920000000-27fff664f04384263f02	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine , positive-QTOF	splash10-014j-0790000000-5653705decf2e797e122	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine , positive-QTOF	splash10-0002-2910000000-63ecec66eeef916c6ccf	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine 10V, Positive-QTOF	splash10-014i-0090000000-7d63abc3646b01e9ca0b	2021-09-20	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine 50V, Positive-QTOF	splash10-0005-0900000000-63232fade3bde30c6818	2021-09-20	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Mirtazapine 50V, Positive-QTOF	splash10-0002-0900000000-678be0a9bfb1ed536c71	2021-09-20	HMDB team, MONA	View Spectrum

Biological Properties

Cellular Locations

Membrane

Biospecimen Locations

Blood
Urine

Tissue Locations

Not Available

Pathways

Name	SMPDB/PathBank	KEGG
Mirtazapine H1-Antihistamine Action		Not Available

Normal Concentrations

Biospecimen	Status	Value	Age	Sex	Condition	Reference	Details
Blood	Expected but not Quantified	Not Quantified	Not Available	Not Available	Taking drug identified by DrugBank entry DB00370	21059682	details
Urine	Expected but not Quantified	Not Quantified	Not Available	Not Available	Taking drug identified by DrugBank entry DB00370	21059682	details

Abnormal Concentrations

Not Available

Predicted Concentrations

Biospecimen	Value	Original age	Original sex	Original condition	Comments
Blood	0.000 uM	Adult (>18 years old)	Both	Normal	Predicted based on drug qualities
Blood	0.000 umol/mmol creatinine	Adult (>18 years old)	Both	Normal	Predicted based on drug qualities

Associated Disorders and Diseases

Disease References

None

Associated OMIM IDs

None

External Links

DrugBank ID

DB00370

Phenol Explorer Compound ID

Not Available

FooDB ID

Not Available

KNApSAcK ID

Not Available

Chemspider ID

4060

KEGG Compound ID

C07570

BioCyc ID

Not Available

BiGG ID

Not Available

Wikipedia Link

Mirtazapine

METLIN ID

Not Available

PubChem Compound

Not Available

PDB ID

Not Available

ChEBI ID

6950

Food Biomarker Ontology

Not Available

VMH ID

Not Available

MarkerDB ID

Not Available

Good Scents ID

Not Available

References

Synthesis Reference

Not Available

Material Safety Data Sheet (MSDS)

Not Available

General References

Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
Burrows GD, Kremer CM: Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. [PubMed:9090576 ]
Fawcett J, Barkin RL: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998 Dec;51(3):267-85. [PubMed:10333982 ]
Velazquez C, Carlson A, Stokes KA, Leikin JB: Relative safety of mirtazapine overdose. Vet Hum Toxicol. 2001 Dec;43(6):342-4. [PubMed:11757992 ]
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [PubMed:16272179 ]
Gillman PK: A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25. [PubMed:16342227 ]

Only showing the first 10 proteins. There are 11 proteins in total.

Show all enzymes and transporters

Enzymes

Enzyme Details

1. Cytochrome P450 3A4

General function:: Involved in monooxygenase activity
Specific function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular weight:: 57255.585

References

Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]

Enzyme Details

2. Cytochrome P450 2C9

General function:: Involved in monooxygenase activity
Specific function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.
Gene Name:: CYP2C9
Uniprot ID:: P11712
Molecular weight:: 55627.365

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Enzyme Details

3. Cytochrome P450 2D6

General function:: Involved in monooxygenase activity
Specific function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Molecular weight:: 55768.94

References

Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]

Enzyme Details

4. Cytochrome P450 1A2

General function:: Involved in monooxygenase activity
Specific function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.
Gene Name:: CYP1A2
Uniprot ID:: P05177
Molecular weight:: 58406.915

References

Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]

Enzyme Details

5. Cytochrome P450 2C8

General function:: Involved in monooxygenase activity
Specific function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).
Gene Name:: CYP2C8
Uniprot ID:: P10632
Molecular weight:: 55824.275

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Enzyme Details

6. Alpha-2A adrenergic receptor

General function:: Involved in G-protein coupled receptor protein signaling pathway
Specific function:: Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol
Gene Name:: ADRA2A
Uniprot ID:: P08913
Molecular weight:: 48956.3

References

Garcia-Sevilla JA, Ventayol P, Perez V, Rubovszky G, Puigdemont D, Ferrer-Alcon M, Andreoli A, Guimon J, Alvarez E: Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology. 2004 Mar;29(3):580-8. [PubMed:14628003 ]
Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
Besson A, Haddjeri N, Blier P, de Montigny C: Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol. 2000 May;10(3):177-88. [PubMed:10793320 ]
Schreiber S, Bleich A, Pick CG: Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression? J Mol Neurosci. 2002 Feb-Apr;18(1-2):143-9. [PubMed:11931344 ]
Rogoz Z, Wrobel A, Dlaboga D, Maj J, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. J Physiol Pharmacol. 2002 Mar;53(1):105-16. [PubMed:11939713 ]
Rogoz Z, Wrobel A, Dlaboga D, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Pol J Pharmacol. 2002 Jul-Aug;54(4):381-9. [PubMed:12523492 ]

Enzyme Details

7. 5-hydroxytryptamine receptor 2A

General function:: Involved in G-protein coupled receptor protein signaling pathway
Specific function:: This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. This receptor is involved in tracheal smooth muscle contraction, bronchoconstriction, and control of aldosterone production
Gene Name:: HTR2A
Uniprot ID:: P28223
Molecular weight:: 52602.6

References

Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. [PubMed:10446734 ]
Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
Nutt DJ: Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 1999;60 Suppl 17:23-7; discussion 46-8. [PubMed:10446738 ]
Laakmann G, Schule C, Baghai T, Waldvogel E: Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology. 1999 Oct;24(7):769-84. [PubMed:10451911 ]
Waldinger MD, Berendsen HH, Schweitzer DH: Treatment of hot flushes with mirtazapine: four case reports. Maturitas. 2000 Oct 31;36(3):165-8. [PubMed:11063897 ]
Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]

Enzyme Details

8. 5-hydroxytryptamine receptor 2C

General function:: Involved in G-protein coupled receptor protein signaling pathway
Specific function:: This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system
Gene Name:: HTR2C
Uniprot ID:: P28335
Molecular weight:: 51820.7

References

Benelli A, Frigeri C, Bertolini A, Genedani S: Influence of mirtazapine on the sexual behavior of male rats. Psychopharmacology (Berl). 2004 Jan;171(3):250-8. Epub 2003 Nov 13. [PubMed:14615872 ]
Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Meert TF, Melis W, Aerts N, Clincke G: Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav Pharmacol. 1997 Aug;8(4):353-63. [PubMed:9832994 ]
Millan MJ: Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. [PubMed:16433010 ]
Dekeyne A, Iob L, Millan MJ: Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Psychopharmacology (Berl). 2001 Jan;153(3):389-92. [PubMed:11271412 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzyme Details

9. Histamine H1 receptor

General function:: Involved in G-protein coupled receptor protein signaling pathway
Specific function:: In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system
Gene Name:: HRH1
Uniprot ID:: P35367
Molecular weight:: 55783.6

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzyme Details

10. 5-hydroxytryptamine receptor 3A

General function:: Involved in extracellular ligand-gated ion channel activity
Specific function:: This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel
Gene Name:: HTR3A
Uniprot ID:: P46098
Molecular weight:: 55279.8

References

Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. [PubMed:10446734 ]
Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
Kast RE, Foley KF: Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). 2007 Jul;16(4):351-4. [PubMed:17587360 ]
de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. [PubMed:8930006 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]

Only showing the first 10 proteins. There are 11 proteins in total.

Show all enzymes and transporters

Showing metabocard for Mirtazapine (HMDB0014514)

MOL for HMDB0014514 (Mirtazapine)

3D MOL for HMDB0014514 (Mirtazapine)

3D SDF for HMDB0014514 (Mirtazapine)

3D-SDF for HMDB0014514 (Mirtazapine)

PDB for HMDB0014514 (Mirtazapine)

3D PDB for HMDB0014514 (Mirtazapine)

SMILES for HMDB0014514 (Mirtazapine)

INCHI for HMDB0014514 (Mirtazapine)

Structure for HMDB0014514 (Mirtazapine)

3D Structure for HMDB0014514 (Mirtazapine)

Experimental Collision Cross Sections

Predicted Collision Cross Sections

Predicted Kovats Retention Indices

Underivatized

GC-MS Spectra

MS/MS Spectra

Enzymes

References

References

References

References

References

References

References

References

References

References